Ticker
ABBV

Price
146.28
Stock movement down
-1.12 (-0.76%)
Company name
AbbVie Inc
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Markedsværdi
258.69B
Ent værdi
372.16B
Pris/omsætning
4.47
Pris/bog
16.14
Udbytte afkast
4.05%
Udbyttevækst
17.11%
Vekst år
9
FCF-udbetaling
44.94%
Efterfølgende P/E
19.30
Fremtidig P/E
12.46
PEG
2.33
EPS-vekst
36.80%
1 års afkast
8.98%
3 års afkast
20.42%
5 års afkast
6.20%
10 års afkast
14.59%
Senest opdateret: 2023-01-27

FORRETNINGSMÆSSIG INDSIGT

Revenues per Product Category ($M)

Loading...
Company comments

AbbVie was created through a spinoff from Abbott Laboratories in 2013

Humira is the world’s #1 global pharmaceutical product by a large margin

AbbVie acquired Allergan, the maker of Botox in 2020, hence the huge jump in revenues and the change in the segment classifications

Geographic Revenues ($M)

Loading...

UDBYTTE

Udbytte — 5 år

Loading...
Data om udbytte
Udbytte pr. aktie5.92
Udbytte4.05%
Udbetaling frekvensKvartalsvis
Maksimalt afkast7.32%
Gennemsnitligt afkast4.73%
Den mindste afkast3.12%
Rabat til gennemsnitligt afkast-16.77%
Opadgående potentiale-14.36%
Retur som% af max afkast55.30%

Udbyttefordeling (invers percentil) — 5 år

Loading...
Data om fordeling af udbytte
Udbytte4.05%
Nuværende afkastfordeling73.25%
Afkast ved 100 % (Min.)3.12%
Afkast ved 90 %3.71%
Afkast ved 80 %3.94%
Afkast ved 50 % (median)4.80%
Afkast ved 20 %5.39%
Afkast ved 10 %5.77%
Udbytte ved 0 % (maks.)7.32%

Udbytte pr. aktie

Loading...
Data om udbytte pr. aktie
År med vækst9 years
CCC-statusDividend Challenger
Udbytte pr. aktie5.92
Udbetaling frekvensKvartalsvis
Ex-div dato12 Jan 2023
EPS (TTM)7.55
EPS (1 år frem)11.74
EPS-vekst (5 år)36.80%
EPS-vækst (5 år fremad)8.27%

Udbyttevækst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om udbyttevækst
ABBVS&P500
DGR MR4.96%11.59%
DGR TTM7.53%10.54%
DGR 3 år9.63%4.00%
DGR 5 år17.11%5.65%
DGR 10 år-7.37%
DGR 15 år-5.83%
Tid siden sidste ændring annonceret93 days
EPS-vekst (5 år)36.80%
EPS-vækst (5 år fremad)8.27%

Udbetalingsforhold

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om udbetalingsforhold
EPS-dekningFCF-dækning
TTM73.48%44.94%
Gennemsnit--
Fremad50.43%-

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E19.30
Pris til OCF11.45
Pris til FCF11.80
Pris til EBITDA10.23
EV i forhold til EBITDA14.71

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning4.47
Pris til egenkapital16.14
EV i forhold til salg6.44

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier1.77B
EPS (TTM)7.55
FCF pr. aktie (TTM)12.34

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)57.82B
Bruttofortjeneste (TTM)40.26B
Driftsindkomst (TTM)17.69B
Nettoindkomst (TTM)13.41B
EPS (TTM)7.55
EPS (1 år frem)11.74

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)69.62%
Driftsmargin (TTM)30.59%
Fortjenstmargin (TTM)23.19%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter11.83B
Nettotilgodehavender10.74B
Omsætningsaktiver i alt30.36B
Goodwill31.73B
Immaterielle aktiver68.72B
Ejendomme, anlæg og udstyr0.00
Sum aktiver141.32B
Kreditor23.50B
Kortfristet/nuværende langsigtet gæld69.61B
Summen af kortfristede forpligtelser32.71B
Sum gæld125.30B
Aktionærernes egenkapital16.03B
Materielle nettoaktiver-84.46B

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)22.59B
Investeringsudgifter (TTM)669.00M
Fri pengestrøm (TTM)21.92B
Udbetalt udbytte (TTM)9.85B

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast83.65%
Afkast af aktiver9.49%
Afkast af investeret kapital15.66%
Kontant afkast af investeret kapital25.60%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning147.31
Daglig høj147.59
Daglig lav146.01
Daglig volumen3.77M
Højeste gennem alle tider174.96
1 års analytiker estimat162.50
Beta0.62
EPS (TTM)7.55
Udbytte pr. aktie5.92
Ex-div dato12 Jan 2023
Næste dato for resultatpræsentation9 Feb 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ABBVS&P500
Nuværende prisfald fra top notering-16.39%-15.08%
Højeste prisfald-48.88%-56.47%
Højeste efterår dato15 Aug 20199 Mar 2009
Gennemsnitlig fald fra toppen-14.21%-11.49%
Gennemsnitlig tid til nyt højdepunkt17 days13 days
Maks. tid til nyt højdepunkt975 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
ABBV (AbbVie Inc) company logo
Markedsværdi
258.69B
Markedsværdi kategori
Large-cap
Beskrivelse
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Personale
50000
Investor relationer
SEC-indsendelser
Adm. direktør
Richard Gonzalez
Land
USA
By
North Chicago
Aktietype
Common stock
CCC-status
Dividend Challenger
Utbyttefrekvens
Kvartalsvis
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
In this article, we will be taking a look at 12 cheap blue chip stocks to buy. To skip our detailed analysis of the stock market, you can go directly to see the 5 Cheap Blue Chip Stocks To Buy. The US...
26. januar 2023
In this article, we will be taking a look at 12 cheap biotech stocks to buy. To skip our detailed analysis of the biotech sector, you can go directly to see 5 Cheap Biotech Stocks To Buy. The biotechn...
25. januar 2023
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'. This ...
25. januar 2023
2023 is expected to be an important year for AbbVie (NYSE: ABBV). The pharmaceutical company is facing its first biosimilar competition in the United States. It's big news because it involves AbbVie...
25. januar 2023
Last year was a tough one for most companies and investors. The three major indexes touched bear territory. And even the strongest of companies saw their share prices slip. Everyone is hoping 2023 wil...
25. januar 2023
In the latest trading session, AbbVie (ABBV) closed at $148.55, marking a -0.7% move from the previous day.
23. januar 2023
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
23. januar 2023
Passive-income stocks are a proven way to cushion your portfolio against market volatility. What's more, top shelf dividend plays also tend to outperform other asset classes in bull markets. Not all...
23. januar 2023
AbbVie (NYSE: ABBV) boasts a portfolio of drugs across immunology, neuroscience, aesthetics, oncology, and eye care. It's because Humira has become a megablockbuster. Humira is the world's top-selli...
22. januar 2023
Investors bought certain stocks hand over fist. In most cases, these particular companies offered investors a solid reason to be optimistic about their future. Up-and-coming biotech Axsome Therapeut...
19. januar 2023
Næste side